CYRAMZA is associated with a distinct spectrum of adverse effects, necessitating proactive management strategies.

Side Effects and Safety Profile

The most common adverse reactions include hypertension, diarrhea, neutropenia, fatigue, proteinuria, epistaxis, and stomatitis, with incidence and severity influenced by the specific regimen and patient factors. Serious risks include hemorrhage, gastrointestinal perforation, arterial thromboembolic events, and infusion-related reactions. Laboratory abnormalities such as elevated liver enzymes, anemia, and thrombocytopenia are also observed. Dose modifications, treatment interruptions, or discontinuation may be required based on toxicity grade. Long-term safety data and rare adverse events are continually monitored in post-marketing surveillance. Pediatric safety and use are not specified in the description.